Home > Research > Publications & Outputs > Small Molecule Drug Discovery for Neglected Tro...

Research

Links

Text available via DOI:

Keywords

View graph of relations

Small Molecule Drug Discovery for Neglected Tropical Snakebite

Research output: Contribution to Journal/Magazine › Review article › peer-review

Published

Standard

Small Molecule Drug Discovery for Neglected Tropical Snakebite. / Clare, Rachel H; Hall, Steven R; Patel, Rohit N et al.
In: Trends in Pharmacological Sciences, Vol. 42, No. 5, 31.05.2021, p. 340-353.

Research output: Contribution to Journal/Magazine › Review article › peer-review

Harvard

Clare, RH, Hall, SR, Patel, RN & Casewell, NR 2021, 'Small Molecule Drug Discovery for Neglected Tropical Snakebite', Trends in Pharmacological Sciences, vol. 42, no. 5, pp. 340-353. https://doi.org/10.1016/j.tips.2021.02.005

APA

Clare, R. H., Hall, S. R., Patel, R. N., & Casewell, N. R. (2021). Small Molecule Drug Discovery for Neglected Tropical Snakebite. Trends in Pharmacological Sciences, 42(5), 340-353. https://doi.org/10.1016/j.tips.2021.02.005

Vancouver

Clare RH, Hall SR, Patel RN, Casewell NR. Small Molecule Drug Discovery for Neglected Tropical Snakebite. Trends in Pharmacological Sciences. 2021 May 31;42(5):340-353. Epub 2021 Apr 15. doi: 10.1016/j.tips.2021.02.005

Author

Clare, Rachel H ; Hall, Steven R ; Patel, Rohit N et al. / Small Molecule Drug Discovery for Neglected Tropical Snakebite. In: Trends in Pharmacological Sciences. 2021 ; Vol. 42, No. 5. pp. 340-353.

Bibtex

@article{00343ab9618343b69eda195dd25b7904,
title = "Small Molecule Drug Discovery for Neglected Tropical Snakebite",
abstract = "Snakebite envenoming is responsible for as many as 138 000 deaths annually, making it the world's most lethal neglected tropical disease (NTD). There is an urgent need to improve snakebite treatment, which currently relies on outdated and poorly tolerated biologic antivenoms that are often weakly efficacious, must be given intravenously in a healthcare setting, and are expensive to those who need them the most. Herein we describe the challenges associated with the discovery and development of new snakebite treatments and detail the great potential of venom toxin-inhibiting small molecule drugs. We finish by highlighting successful enabling strategies applied to other NTDs that could be exploited to facilitate the development of next-generation small molecule-based snakebite treatments.",
keywords = "Antivenoms, Delivery of Health Care, Drug Discovery, Humans, Neglected Diseases/drug therapy, Snake Bites/drug therapy",
author = "Clare, {Rachel H} and Hall, {Steven R} and Patel, {Rohit N} and Casewell, {Nicholas R}",
year = "2021",
month = may,
day = "31",
doi = "10.1016/j.tips.2021.02.005",
language = "English",
volume = "42",
pages = "340--353",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "5",

}

RIS

TY - JOUR

T1 - Small Molecule Drug Discovery for Neglected Tropical Snakebite

AU - Clare, Rachel H

AU - Hall, Steven R

AU - Patel, Rohit N

AU - Casewell, Nicholas R

PY - 2021/5/31

Y1 - 2021/5/31

N2 - Snakebite envenoming is responsible for as many as 138 000 deaths annually, making it the world's most lethal neglected tropical disease (NTD). There is an urgent need to improve snakebite treatment, which currently relies on outdated and poorly tolerated biologic antivenoms that are often weakly efficacious, must be given intravenously in a healthcare setting, and are expensive to those who need them the most. Herein we describe the challenges associated with the discovery and development of new snakebite treatments and detail the great potential of venom toxin-inhibiting small molecule drugs. We finish by highlighting successful enabling strategies applied to other NTDs that could be exploited to facilitate the development of next-generation small molecule-based snakebite treatments.

AB - Snakebite envenoming is responsible for as many as 138 000 deaths annually, making it the world's most lethal neglected tropical disease (NTD). There is an urgent need to improve snakebite treatment, which currently relies on outdated and poorly tolerated biologic antivenoms that are often weakly efficacious, must be given intravenously in a healthcare setting, and are expensive to those who need them the most. Herein we describe the challenges associated with the discovery and development of new snakebite treatments and detail the great potential of venom toxin-inhibiting small molecule drugs. We finish by highlighting successful enabling strategies applied to other NTDs that could be exploited to facilitate the development of next-generation small molecule-based snakebite treatments.

KW - Antivenoms

KW - Delivery of Health Care

KW - Drug Discovery

KW - Humans

KW - Neglected Diseases/drug therapy

KW - Snake Bites/drug therapy

U2 - 10.1016/j.tips.2021.02.005

DO - 10.1016/j.tips.2021.02.005

M3 - Review article

C2 - 33773806

VL - 42

SP - 340

EP - 353

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 5

ER -